November 20, 2020
A Phase 3 Trial for AMT-061, a gene therapy treatment for hemophilia B being developed by uniQure, showed increased factor IX activity and controlled bleeding while markedly reducing the need for other treatments.
Links to articles listed may take readers to websites separate and out of the control of the CU School of Medicine and the Hemophilia and Thrombosis Center. The CU School of Medicine and the Hemophilia and Thrombosis Center are not responsible for any errors, inaccuracies or opinions that may be expressed in any of the linked articles.
Previous articles featured on our website can be found at our archive page here. Please note that links in our archive files may take readers to websites that may have changed their link. In some cases these links do not work anymore. We periodically check and remove articles that have broken links. If you have questions about these articles, please contact us at firstname.lastname@example.org.